含Ⅲ型纖連蛋白域蛋白5(FNDC5)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. by FLIA (Flow Luminescence Immunoassay)
FRCP2; Irisin; Fibronectin type III repeat-containing protein 2
（注：單次混測多因子不超過8個指標 ）
- 編號LMN576Mu
- 物種Mus musculus (Mouse，小鼠)相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應時長3.5h
- 檢測范圍0.98-1000pg/mL
- 靈敏度最小可檢測劑量小于等于0.327 pg/mL.
- 樣本類型Serum, plasma and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格8指標數(shù)7指標數(shù)6指標數(shù)5指標數(shù)4指標數(shù)3指標數(shù)2指標數(shù)1指標數(shù)
- 價格¥ 2964¥ 3078¥ 3249¥ 3477¥ 3705¥ 4047¥ 4560¥ 5700 添加到價格計算器 計算器
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
本試劑盒用于檢測含Ⅲ型纖連蛋白域蛋白5(FNDC5)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應。
由于受到技術及樣本來源的限制，不可能完成對所有相關或相似物質(zhì)交叉反應檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應。
回收率
分別于定值血清及血漿樣本中加入一定量的含Ⅲ型纖連蛋白域蛋白5(FNDC5)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標樣品），重復測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 79-99 | 88 |
| EDTA plasma(n=5) | 85-92 | 88 |
| heparin plasma(n=5) | 87-103 | 92 |
| sodium citrate plasma(n=5) | 98-105 | 101 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定，每個樣本使用同一試劑盒重復測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的含Ⅲ型纖連蛋白域蛋白5(FNDC5)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中含Ⅲ型纖連蛋白域蛋白5(FNDC5)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 97-105% | 80-105% | 91-98% | 84-99% |
| EDTA plasma(n=5) | 86-103% | 81-101% | 94-101% | 95-102% |
| heparin plasma(n=5) | 89-96% | 88-95% | 83-94% | 85-97% |
| sodium citrate plasma(n=5) | 90-105% | 99-105% | 80-95% | 96-105% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本準備；
2. 加樣（標準品、樣本、磁珠）標準品或樣本100μL及磁珠10μL，
37°C酶標板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將含Ⅲ型纖連蛋白域蛋白5(FNDC5)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標準品或標本以及磁珠，其中的含Ⅲ型纖連蛋白域蛋白5(FNDC5)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的含Ⅲ型纖連蛋白域蛋白5(FNDC5)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標記的親和素，再次徹底洗滌后即可上機讀數(shù)。MFI值和樣品中的含Ⅲ型纖連蛋白域蛋白5(FNDC5)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關。
贈品
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| APN576Mu61 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)活性蛋白 | Cell?culture;?Activity?Assays. |
| APN576Mu01 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPN576Mu01 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Mu02 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAN576Mu02 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)多克隆抗體 | WB; IHC; ICC; IP. |
| PAN576Mu01 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)多克隆抗體 | WB; IHC; ICC; IP. |
| SEN576Mu | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMN576Mu | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Diabetes Research and Clinical Practice | Serum irisin levels in new-onset type 2 diabetes[PubMed: 23369227] |
| Journal of diabetes and its complications | Lower circulating irisin is associated with type 2 diabetes mellitus[Pubmed: 23619195] |
| Horm Metab Res. | Inconsistency in circulating irisin levels: what is really happening[Pubmed:24459033] |
| Int J Obes (Lond). | Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice[Pubmed:25199621] |
| Molecular and Cellular Endocrinology | Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice[Pubmed:25576856] |
| journal of diabetes | Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis[PubMed: 25494632] |
| The Journal of Maternal-Fetal & Neonatal Medicine | Maternal circulating levels of irisin in intrahepatic cholestasis of pregnancy[PubMed: 26689349] |
| Hormone and Metabolic Research | Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis[Pubmed:27300472] |
| Nature Reviews Endocrinology | Physiology and role of irisin in glucose homeostasis.[pubmed:28211512] |
| Journal of Molecular and Cellular Cardiology | Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice[pubmed:27638193] |
| Biochemical and Biophysical Research Communications | Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma [pubmed:28867187] |
| PLoS One | Differential actions of PPAR-α and PPAR-β/δ on beige adipocyte formation: A study in the subcutaneous white adipose tissue of obese male mice[Pubmed:29351550] |
| International Brazilian Journal of?Urology | The Diagnostic Value of FNDC5/Irisin in Renal Cell Cancer.[Pubmed:29522296] |
| Redox Biology | Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative?…[Doi: 10.1016/j.redox.2018.10.019] |
| Antioxidants & redox signaling | Low serum irisin concentration is associated with poor outcomes in patients with acute pancreatitis and irisin administration protects against experimental acute?…[Pubmed: 31250660] |
| Journal of Maternal-Fetal & Neonatal Medicine | Maternal serum, placental, and umbilical venous blood irisin levels in intrahepatic cholestasis of pregnancy[Pubmed: 31590596] |
| Biomed Pharmacother | Identification of irisin as a therapeutic agent that inhibits oxidative stress and fibrosis in a murine model of chronic pancreatitis[Pubmed: 32199226] |
| Irisin Improves Autophagy of Aged Hepatocytes via Increasing Telomerase Activity in Liver Injury[Pubmed: 31976032] | |
| Serum Irisin Predicts Posthepatectomy Complications in Patients with Hepatocellular Carcinoma[Pubmed: 31976024] | |
| DOMESTIC ANIMAL ENDOCRINOLOGY | The myokine Irisin: localization and effects in swine late medium and large antral ovarian follicle[Pubmed: 33120167] |
| Journal of Biomaterials and Tissue Engineering | The Combination of Aerobic and Resistance Exercise Induces Weight Loss via the PGC-1α/Irisin/UCP-1 Pathway[] |
| Evaluation of a recombinant bacillus calmette-guérin vaccine expressing P39-L7/L12 of Brucella melitensis: An immunization strategy against brucellosis in BALB/c …[] | |
| Eur Rev Med Pharmacol Sci | Salivary Irisin: potential inflammatory biomarker in recurrent apthous stomatitis patients[33755963] |
| Metabolites | Pattern of Adiponectin, Osteocalcin, Irisin, FGF-21, and MCP-1 According to the Body Size Phenotype: Could They Be Markers of Metabolic Health in Mexican-Mestizo?…[34822430] |
| Eat Weight Disord | Time-restricted feeding prevents metabolic diseases through the regulation of galanin/GALR1 expression in the hypothalamus of mice[34370270] |
| Ir J Med Sci | Eight-week exercise program improved the quality of life of Alzheimer's patients through functional, cognitive, and biochemical parameters[Pubmed:35604540] |
| Biomed Pharmacother | Irisin attenuates sepsis-induced cardiac dysfunction by attenuating inflammation-induced pyroptosis through a mitochondrial ubiquitin ligase-dependent?…[Pubmed:35653888] |
| Journal of King Saud University - Science | Interaction of nitric oxide synthase and mitochondrial ATP-sensitive potassium channels in protective impacts of combination therapy with irisin?…[] |